^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | AFM13/AB-101 (NK cell stimulant, CD16A agonist, CD30 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AFFIMED RECEIVES FDA FAST TRACK DESIGNATION FOR AFM13 IN COMBINATION WITH ALLONK® FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
Published date:
09/12/2023
Excerpt:
Affimed...announced that the FDA has granted fast track designation to the combination of its innate cell engager (ICE®) AFM13 with AlloNK® for the potential treatment of relapsed/refractory (r/r) Hodgkin lymphoma (HL)....The combination treatment is entering Phase 2 development and will be investigated in Affimed’s LuminICE-203 study (NCT05883449), which received IND-clearance earlier this year; the study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.
